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The presence of the EF-hand-calcium-binding protein S100A4 in the carcinoma cells of the primary tumour is associated with
a shorter survival time of a group of breast cancer patients. In colon cancer, primary tumours as well as metastases to the liver
can be studied. Here we show, using quantitative PCR applied to RNA from 24 normal colon, four liver tissues, 24 colon
carcinoma specimens, and 24 livers containing colonic carcinoma metastases, that the level of S100A4 mRNA was signiﬁcantly
higher in the carcinomas compared to normal specimens (Mann-Whitney U-test, P=0.05), and in liver metastases compared to
carcinoma specimens (P=0.039). The latter comparison included seven liver metastases and their matched primary carcinomas
(P50.001) from the same patient. In situ hybridization and immunocytochemistry techniques have localized S100A4 to both
carcinoma cells and lymphocytes in the malignant specimens. The percentage of specimens stained for S100A4 in the epithelial
cells is signiﬁcantly higher for those isolated from carcinomas and metastases than from the corresponding normal tissue, and
from metastases than from corresponding carcinoma (Fisher Exact text, P50.0016, P=0.04, respectively). In most specimens,
S100A4 is present in clusters of T lymphocytes and this distribution is also found in the lymphoid, uninﬂamed appendix.
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The EF-hand-containing protein, S100A4 (p9Ka) is closely linked
with the ability of mammary tumour cells to metastasize in experi-
mental model systems. Transfection of the gene for rat (Davies et
al, 1993) or human (Lloyd et al, 1998) S100A4 into benign rat
mammary cells, and the expression of S100A4 protein at an
elevated level leads to the expression of a metastatic phenotype.
Similar results have been obtained by over-expressing the mouse
S100A4 in human MCF-7 cells (Grigorian et al, 1999). Mice, trans-
genic for the S100A4 gene, which over express S100A4, show no
phenotype, but when these mice are mated with mice bearing, as
an expressed transgene, an activated oncogene, such as c-erbB-2,
which produces benign mammary tumours, offspring which
express both the onco-transgene and the S100A4 transgene, exhibit
tumours which also metastasize to the lungs (Davies et al, 1996). A
similar result was obtained when transgenic mice bearing the
mouse S100A4 transgene were mated with a strain of mice which
yielded MMTV-induced mammary tumours (Ambartsumian et al,
1996).
In a study of 349 patients with breast cancer, the presence of
immunocytochemically-detectable S100A4 in the primary tumours
is associated with their early demise when followed up for 19 years
(Platt-Higgins et al, 2000; Rudland et al, 2000). This result suggests a
direct link, at least in this group of patients, between the presence of
S100A4 in the carcinoma cells of the primary tumour and the
process of metastasis, since it is commonly believed that breast
cancer patients die of metastatic spread to sites other than that of
the lymph nodes. Thus it is important to establish whether the cells
which metastasize to these distant sites are the cells which contain
high levels of S100A4. However, it is not possible to study easily,
the distant metastases which arise from the primary tumour of
breast cancer, since metastatic spread in breast cancer is predomi-
nantly to surgically inaccessible sites such as the bones and brain
of the patients. In contrast the primary tumour of colon carcinomas
metastasises at a relatively high frequency to the liver, and patholo-
gical tissue from liver containing such metastases is frequently
surgically resected and is therefore available. Thus, the levels of
S100A4 have been determined in the primary tumour of colon carci-
nomas and corresponding liver metastases using quantitative
polymerase chain reaction, in situ hybridization and immunocyto-
chemical techniques. The results suggest that some variability in
the level of S100A4 in tissue specimens is due to inﬁltrating cells,
such as T-lymphocytes, but that S100A4 is present at a higher level
in the carcinoma cells of liver metastases derived from colon carci-
nomas than the corresponding primary colon carcinomas.
MATERIALS AND METHODS
Tissue specimens
Tissue specimens were obtained with ethical approval and full
informed consent from patients treated at the Royal Liverpool
University Hospital between 1993 and 2000. Primary colon carci-
noma, adjacent normal colon from specimens resected for colon
carcinoma, liver metastases, adjacent normal liver from specimens
resected for cancer in the liver, and specimens of colon adenoma
were snap frozen in liquid nitrogen within 1 h of surgery. The
frozen tissue was stored at 71408C until processed for isolation
of RNA. Adjacent samples were ﬁxed in formalin prior to being
embedded in parafﬁn wax. Six mm serial sections were cut for
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www.bjcancer.comimmunocytochemistry and in situ hybridization, the latter under
RNase-free conditions (Taylor et al, 1999). The pathological details
of the specimens studied are shown in Table 1. Normal appendix
was obtained from a right hemicolectomy specimen removed for
adenocarcinoma of the transverse colon.
Immunocytochemistry
Sections of formalin-ﬁxed parafﬁn-embedded material were dried
overnight at 378C, dewaxed in xylene and rehydrated through
graded concentrations of ethanol. Peroxidases were blocked using
1% H2O2 in methanol for 12 min. Immunocytochemistry for
S100A4 was carried out as described previously (Rudland et al,
2000). The primary S100A4 antibody (DAKO, Ely Cambs., UK)
was used at a dilution of 1:400, and was incubated with the sections
overnight. The secondary antibody, donkey anti-rabbit IgG, was
used at a dilution of 1:300. Sections were counterstained with
Mayers haemalum and mounted in DPX (BDH, Nottingham, UK).
To compare the localization of S100A4 within the two major
types of lymphocytes, T and B cells, immunocytochemistry was
performed on 5 mm serial sections of formalin-ﬁxed, parafﬁn-
embedded normal appendix. The antibodies to CD79a (B cells) and
to CD3 (T-cells) were obtained from DAKO (Ely, Cambs., UK)
and are speciﬁc for their respective subgroup of lymphocytes
(Chetty and Gatter, 1994; Mason et al, 1995).
Immunocytochemistry for all three antibodies was performed
with the Dako Envision horseradish peroxidase system using
diaminobenzidine (DAB) as the chromogen. Prior to incubation
of sections of appendix with the primary antibodies, they were
heated in 10 mM EDTANa2 pH 7.0 in a pressure cooker at
10 p.s.i. for 2.5 min for retrieval of antigens. All washes between
each stage were performed with Tris buffered saline (TBS)
(50 mM Tris-HCl (pH 7.4), 150 mM NaCl).
Monoclonal antibodies to lymphocyte antigens were diluted
1:50 and antibodies to S100A4 were diluted 1:200 in 5% (w/v)
bovine serum albumin in TBS (pH 7.4). They were applied to
the tissue sections for 40 min at room temperature, after a pre-
treatment of the sections with 5% (w/v) bovine serum albumin
in TBS (pH 7.4) for 10 min for the polyclonal antiserum to
S100A4. All subsequent steps followed the polyclonal and MAb
protocols supplied with the Dako Envision+ HRP system. The
appropriately labelled polymer was applied for 30 min, washed
with buffer and the horseradish peroxidase was visualized with
DAB/water solution supplied with the DAKO Envision kit. Sections
were counterstained with Mayer’s haemalum for 30 s and
processed as above.
Competitive RT–PCR for S100A4 mRNA
Competitive RT–PCR to quantify S100A4 mRNA was based upon
a previously-described method (Taylor et al, 1998) with the follow-
ing modiﬁcations. Primers 1 and 2 (Figure 1) were used in RT–
PCR reactions to create a PCR product that contained a T7 tran-
scription sequence. This PCR product coupled with T7 RNA
polymerase produced an S100A4-speciﬁc competitor RNA that
was 82 bp shorter than the target fragment of S100A4 mRNA. Both
target and competitor S100A4 mRNA were ampliﬁed using primers
3 and 4 in the same reaction (Figure 1). The competitor RNA was
quantiﬁed precisely by measuring its optical density at 260 nM, and
10 serial two-fold dilutions were prepared containing known
concentrations of competitor RNA ranging from 20000–
39 pg ml
71. In the reverse-transcription reaction, 0.5 mg of primer
3 (Figure 1), a known amount of competitor RNA and 500 ng of
target RNA were incubated at 568C for 10 min before being placed
on ice. The Superscript mixture (GIBCO–BRL, Paisley Scotland,
UK) was added before being placed at 378C for 1 h. The PCR reac-
tion mixture contained 16PCR buffer (GIBCO–BRL), 10 pmol
each of primers 3 and 4 (Figure 1), 2 mM MgCl2, 0.02% (w/v)
detergent W-1, 0.2 mM dNTPs and 1.5 units Taq DNA polymerase
(GIBCO–BRL). The temperature cycling proﬁle for ampliﬁcation
was: one step of 958C for 5 min, followed by 30 cycles of 958C
for 45 s, 568C for 45 s and 728C extension for 45 s. A ﬁnal step
of 728C for 10 min completed any unﬁnished extensions. Co-
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Table 1 Source of specimens used in competitive PCR and immuno-
cytochemistry
Total number of used specimens 79
Total number of normal specimens 24
Consisting of:
normal ileum 1
normal caecum 4
normal ascending colon 2
normal sigmoid colon 10
normal rectosigmoid 1
normal rectum 2
normal colon (not otherwise speciﬁed) 4
Total number of adenoma specimens 3
Total number of colon carcinoma specimens 24
Consisting of:
adenocarcinoma of the caecum 5
adenocarcinoma of the ascending colon 4
adenocarcinoma of the sigmoid colon 8
adenocarcinoma of the rectosigmoid junction 2
adenocarcinoma of the rectum 2
adenocarcinoma not otherwise speciﬁed 1
mucinous adenocarcinoma of the ascending colon 2
Total number of liver metastasis specimens 24
Consisting of:
hepatic metastatic adenocarcinoma from colon 22
metastatic mucinous adenocarcinoma 1
metastatic adenocarcinoma with ﬁbrosis 1
Total number of normal liver specimens 4
Primer 1: 5' TCT TCC TGG GCT TAT CTC TGT TGC TGT CCA AGT TGC T 3'.
3' primer complementary to positions 2696–2677 and 2592–2573 of the human S100A4 gene (GenBank accession number Z33457) used to
produce the competitor containing an 82-bp deletion.
Primer 2: 5' AAT TTA ATA CGA CTC ACT ATA GGG ATC TTC CCC TCT CTA CAA C 3'.
5' primer complementary to positions 670–687 of the human S100A4 gene (GenBank accession number Z33457) and containing a T7
polymerase recognition sequence at its 5' end.
Primer 3: 5' TTC CTG GGC TGC TTA TCT 3'.
3' PCR amplification primer, complementary to nucleotides 2694–2677 of the human S100A4 gene (GenBank accession number Z33457).
Primer 4: 5' TCT TCC CCT CTC TAC AAC 3'.
5' PCR amplification primer, complementary to nucleotides 670–687 of the human S100A4 gene (GenBank accession number Z33457).
Figure 1 Primers used for competitive reverse-transcript polymerase chain reaction. The recognition sequence for T7 RNA polymerase, used to make
the competitor RNA, is underlined.
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British Journal of Cancer (2002) 86(3), 409–416 ã 2002 The Cancer Research Campaignampliﬁcation of target and competitor with primers 3 and 4
produced fragments of 366 and 284 bp, respectively. RNA from
one carcinoma specimen (sample 56) was included in each run
of competitive PCR as a normalizing control.
Preparation of RNA probes for in situ hybridization
A 334 bp fragment of the 3' end of the human S100A4 cDNA
consisting of part of exon 3 to the poly(A) addition sequence
(position 6940–7274 of the DNA sequence, Genbank accession
number Z33457) was ampliﬁed by PCR and cloned into the EcoRI
and NotI restriction enzyme sites of pBluescript (Stratagene,
Amsterdam, The Netherlands). Plasmid containing the S100A4
fragment was linearized with either restriction enzymes EcoRI or
NotI (Roche, Lewes, UK) prior to transcription of antisense and
sense RNA’s from the T3 and T7 promoters, respectively, as
described previously (Taylor et al, 1999). Transcripts were puriﬁed
in vitro from template DNA, labelled with Digoxygenin (DIG)
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Figure 2 Competitive RT–PCR of S100A4 mRNA from tissue and tumour specimens. RNA isolated from specimens of (A) normal colon, benign
colonic adenoma, colon carcinoma, liver with metastases, normal liver and (B) a sub-group of linked specimens of colon carcinomas and metastases in
the same patients were subjected to quantitative RT–PCR and the level of S100A4 mRNA expressed as a percentage of that of one of the specimens
(specimen 56) which was included in each experiment to allow comparison of samples analyzed in different experiments. The error bars represent
+s.d. of two experiments. The mean level for each group of specimens is shown by the horizontal lines in A.
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(Taylor et al, 1999). RNA probes were stored in aliquots at 7808C
until required.
In situ hybridization
In situ hybridization was performed on histological sections as
described previously (Taylor et al, 1999). Brieﬂy, the sections were
dewaxed and rehydrated before being treated with proteinase K
(Sigma, New Orleans, USA) for 30 min at 378C. Sections were
post-ﬁxed in 4% (w/v) paraformaldehyde, acetylated and prehybri-
dized before being incubated with 100 ng slide
71 of the
appropriate RNA sense or antisense probe in hybridization buffer
(Taylor et al, 1999). Sections of each tissue specimen were incu-
bated with antisense or sense probes. After a stringent washing
procedure (Taylor et al, 1999), sections were blocked with blocking
reagent (Roche) and then incubated with 1:400 dilution of anti-
DIG-conjugated to alkaline phosphatase (FAB fragment, Roche),
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Figure 3 Box and Whisker plot of S100A4 mRNA levels in normal tissue and tumour specimens by quantitative competitive PCR. RNA isolated for tissue
specimens was subjected to quantitative competitor PCR and the levels of S100A4 mRNA determined as a per cent of the control specimen, number 56.
The median, upper and lower quartile, maximum and minimum value of the levels of S100A4 mRNA are shown as numbers beneath each Box and Whisker
plot for specimens of (A) normal colon, (B) colon carcinoma, (C) liver metastases derived from colon carcinoma, (D) normal liver, (E) linked carcinoma and
(F) linked liver metastases. The arrows below the boxes point to the values of the means. The width of the boxes represents the number of specimens in
each group, which is also shown in bold alongside each plot.
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British Journal of Cancer (2002) 86(3), 409–416 ã 2002 The Cancer Research Campaignbefore the detection solution containing nitro blue tetrazolium salt
(NBT), chloro-3-indolyl-phosphate (BCIP) and levamisole was
added and the slides were left for 16 h in the dark in a Hybaid
Omnislide unit for colour to develop at room temperature. Three
independent observers assessed the resulting stained sections for
the level of staining.
RESULTS
The levels of S100A4 mRNA in RNA isolated from 24 specimens
each of normal colon, colon carcinoma and liver metastases
derived from colon carcinomas, three specimens of benign aden-
oma of the colon, and four specimens of normal liver were deter-
mined by quantitative competitor RT–PCR, as described in
Materials and Methods (Figure 2A). Amounts of S100A4 mRNA/
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Figure 4 In situ hybridization and immunocytochemical staining of tissue and tumour specimens. Histological sections of specimens of liver containing
metastases (A–C), of primary colon carcinoma (D–I), and normal liver (J–L) were subjected to in situ hybridization (A,B,D,E,G,H,J,K) with sense
(A,D,G,J) or antisense (B,E,H,K) probes corresponding to S100A4 mRNA, or subjected to immunocytochemistry with anti-S100A4 serum (C,F,I,L)
as described in Materials and Methods. Following development of colour, images of the sections were digitized and printed. Arrows show stained lympho-
cytes. Magniﬁcation 6144 (A–C, J–L), 672 (D–I); bar on A=50 mm, bar on D=100 mm.
Table 2 Proportion of specimens exhibiting epithelial and lymphocyte
staining for S100A4 protein
No of specimens with:
Specimen type Epithelial staining Lymphocytic staining
Normal liver 0/4 4/4
Normal colonic tissue 0/24 24/24
Adenoma 1/3
a 3/3
Primary colon carcinoma 9/24
b 23/24
Liver metastases 17/24
c 23/24
aNot signiﬁcantly different from normal colon.
bSigniﬁcantly different from normal
colon (P=0.0016, Fisher exact test).
cSigniﬁcantly different from normal colon
(P50.0001, Fisher exact test); signiﬁcantly different from primary colon carcinoma
(P=0.041, Fisher exact test).
S100A4 in colon carcinomas
S Taylor et al
413
ã 2002 The Cancer Research Campaign British Journal of Cancer (2002) 86(3), 409–416500 ng of total RNA from each tissue were expressed as a percen-
tage relative to one specimen of colon carcinoma (labelled Sample
56 in Figure 2). Generally low levels of S100A4 mRNA, relative
to the control specimen 56, were evident in the normal tissue
specimens from colon (mean=19.8%+s.e.2.0) and liver
(mean=14%+s.e. 4.5). However, higher mean levels of S100A4
mRNA in the RNA from the specimens of colon carcinomas
(mean=30%+s.e. 4.3) and liver metastases from colon carcinoma
patients (mean=49%+s.e. 7.2) were clearly evident over those in
the normal tissues. A preliminary analysis of variance using the
Kruskal–Wallace Test indicated that colon carcinoma vs normal
liver, colon carcinoma vs normal colon, liver metastases vs normal
liver, liver metastases vs normal colon, and liver metastases vs colon
carcinomas were likely to be statistically signiﬁcantly different. The
statistically signiﬁcant differences were conﬁrmed using a two-
tailed Mann–Whitney U-Test (P values, respectively=0.042, 0.05,
0.012, 0.0003, 0.039) and the results are shown as Box and Whisker
plots (Figure 3A–D). An additional set of specimens from seven
patients was available consisting of samples of colon carcinoma
and of liver metastases from the same individual. These paired
specimens of primary carcinoma and secondary liver metastases
exhibited mean values of S100A4 mRNA of 22.7%+s.e. 2.6 and
57.5%+s.e. 10.9 respectively. These values represented a statisti-
cally-signiﬁcant higher level of S100A4 mRNA in the liver
metastases than in the primary cancer specimens (Figures 2B and
3E,F) when analyzed either as two groups (P50.001, two-tailed
Mann–Whitney U-Test) or as matched pairs (P50.015, Wilcoxon
Signed Rank Pairs test). When the colon carcinomas were subdi-
vided according to the Duke’s classiﬁcation, the S100A4 mRNA
levels for class A (non invasive), class B (invasive with no nodal
involvement), class C (metastasis to regional lymph nodes) were
not signiﬁcantly different (A vs B, P=0.933; A vs C, P=0.888; B
vs C, P=0.11; 2-tailed Mann–Whitney U-Test.
In order to identify the source of the S100A4 in the tissue
specimens, histological sections of the specimens were subjected
to in situ hybridization using sense and anti-sense probes for
S100A4 mRNA, as described in Materials and Methods. There
was very little S100A4 mRNA in normal liver (Figure 4J,K),
however, immunocytochemical staining of sections identiﬁed
S100A4 protein in scattered cells (Figure 4L) which had the
appearance of lymphocytes (arrows). However, in liver which
contained metastases, there was strong staining of the carcinoma
cells for S100A4 mRNA with the antisense probe (Figure 4B),
but not with the sense probe (Figure 4A), under the same condi-
tions. The presence of S100A4 in the carcinoma cells in the liver
was conﬁrmed by immunocytochemical staining with an antibody
to S100A4 (Figure 4C). When in situ hybridization was carried
out on some specimens of primary colon carcinoma which were
positive for S100A4 mRNA in the quantitative RT–PCR assay,
staining for this mRNA was evident in the carcinoma cells when
the antisense probe (Figure 4E), but not the sense probe (Figure
4D) was used. The presence of S100A4 protein in the carcinoma
cells was conﬁrmed by immunocytochemical staining (Figure 4F).
However, in situ hybridization revealed that in some other speci-
mens of colon carcinoma which were positive in the quantitative
RT–PCR assay, S100A4 mRNA appeared not to be generally
present in the carcinoma cells (Figure 4G,H). This staining
together with immunocytochemical staining of such specimens,
localized the S100A4 mRNA/protein to clusters of small cells in
the cancer specimen, which had the histological appearance of
lymphocytes (Figure 4H,I). In the light of this ﬁnding, histological
sections of all the specimens of normal colon, adenoma, colon
carcinoma, normal liver and metastatic tumours in the liver were
subjected to immunocytochemical staining for S100A4, and the
presence of the S100A4 protein in epithelial cells and lymphocytes
was assessed (Table 2). Of the 24 specimens of normal colon and
four specimens of normal liver, all detectable S100A4 immuno-
cytochemical staining was present in lymphocytes. All three of
the adenomatous colon specimens exhibited lymphocyte staining
with S100A4 being additionally present in the epithelial cells in
one of the specimens. Nine of the 24 colon carcinoma specimens
exhibited signiﬁcant staining of the carcinoma cells, with three at
a high level, and only in one of these specimens did the lympho-
cytes fail to stain for S100A4. Moreover 17 of the specimens of
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Figure 5 Immunocytochemical staining for (A) S100A4, (B) CD3 and
(C) CD79a antigen in serial sections of the lamina propria of normal
appendix. Staining for S100A4 can be seen to mirror that for CD3 (T cell
marker) but not the pattern of CD79a (B cell marker). Arrows point to
lymphocytes in the same regions on the serial sections. Magniﬁcation
6223, bar=50 mm.
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oma cells (Fisher exact test, P50.0001), however, only in one
of the carcinoma specimens did the lymphocytes fail to stain
for S100A4 (Table 2).
In order to ﬁnd out whether a particular subtype of lymphocytes
contained the S100A4, serial sections of some tumour specimens
were immunocytochemically stained with antibodies to S100A4,
and also with antibodies to CD3 and CD79a antigens for T and
B lymphocytes, respectively. S100A4 appeared to be associated with
T lymphocytes (not shown), but the close association of T and B
lymphocytes in the tumours prevented a ﬁrm conclusion to be
drawn. Thus, serial sections of normal specimens of a human tissue
with a characteristic distribution of T and B lymphocytes, namely
human appendix, were similarly stained. S100A4 clearly co-loca-
lized to the region of the appendix containing predominantly
immunocytochemically-determined T cells but not to the region
containing predominantly immunocytochemically-determined B
cells (Figure 5 arrows). Immunocytochemical staining for S100A4
(Figure 5A) was associated with individual cells staining for CD3
antigen (T lymphocytes) (Figure 5B), but not with cells staining
for CD79a antigen (B lymphocytes) (Figure 5C).
DISCUSSION
S100A4 has been shown to cause metastasis in rodent models of
breast cancer (Davies et al, 1993, 1996; Ambartsumian et al,
1996), and its presence in breast cancer cells is strongly associated
with death of a group of patients with human breast cancer (Platt-
Higgins et al, 2000; Rudland et al, 2000). Using quantitative RT–
PCR and in situ hybridization, S100A4 mRNA is found to be
present in normal human colon and liver at only low levels. This
result is in agreement with the previous ﬁnding that immunocyto-
chemically-detected S100A4 is present at only a low level in colon
and liver in the rat (Gibbs et al, 1995). Using competitive RT–
PCR, the levels of S100A4 mRNA increase successively and signiﬁ-
cantly between normal tissue, carcinoma and liver metastases, and
in every single matched case, the level of S100A4 mRNA is signiﬁ-
cantly higher in the liver metastases than the primary carcinoma.
However using in situ hybridization techniques, S100A4 mRNA is
found associated with both the colon carcinoma cells as well as
other non-parenchymal cell types including lymphocytes, which
suggests that both these cell types are synthesizing S100A4. Using
immunocytochemistry, these results are broadly conﬁrmed, the
proportion of specimens with epithelial cells staining for S100A4
increases successively between normal tissue, carcinoma and liver
metastases. In contrast, staining of lymphocytes for S100A4
remained at a consistently high value across the spectrum of
tissues, in agreement with previous work in the breast (Nikitenko
et al, 2000). Since there was no signiﬁcant differences between
the levels of S100A4 mRNA in different Duke subtypes of colon
carcinoma, it is possible that expression of higher levels of
S100A4 are required more for dissemination to distant metastatic
sites than for local invasion and dissemination to regional lymph
nodes. This idea is supported by immunocytochemical experiments
(Bronckart et al, 2001) in which there was no statistically-signiﬁ-
cant difference between normal colon and non-metastatic colon
carcinoma specimens when the proportion of specimens staining
for S100A4 was examined. However, in the same study (Bronckart
et al, 2001), it was found that the percentage of epithelial or
connective tissue cells staining for S100A4 decreased with increas-
ing malignancy grade amongst dysplastic lesions and carcinomas.
That this trend was not observed in the present experiments is
likely to be due to the small number of benign lesions available.
Our results are broadly consistent with those obtained
previously (Takenaga et al, 1997) where a similar increase in
immunocytochemically-detected S100A4 was observed in malignant
relative to non-malignant colonic tumour specimens. Moreover the
deeper, more invasive regions of the specimens in that study were
enhanced in immunocytochemically detectable S100A4, suggesting
an association of higher levels of S100A4 protein with the invading
regions of the tumours (Takenaga et al, 1997). However, in the
present experiments, the proportions of specimens exhibiting posi-
tive staining of the epithelial cells for S100A4 were somewhat
different from those in the previous study, 33% of adenomas posi-
tive (0% positive, previously), 38% of adenocarcinoma specimens
positive (94% positive, previously), 71% of liver metastases positive
(100% positive, previously). Whilst the small number (three) of
adenoma specimens used in the present study may have contribu-
ted to the different results with this group of specimens, this is
unlikely to be the explanation for the carcinomas and liver metas-
tases, since 24 specimens of each were used. It is possible that the
quantitative differences between the two studies may have arisen
from differences in the nature of the specimens used.
Recently, in a separate study, S100A4 levels as detected by Western
blotting, were found to be higher in seven of 12 colon adenocarcino-
ma specimens than in adjacent normal tissue. However, the result was
found not to be statistically signiﬁcant (Komatsu et al, 2001). Whilst
it is possible that S100A4 protein was also elevated in the adjacent
normal tissue, it is more likely that this result arises from variability
in the levels of S100A4 in the carcinoma specimens as measured by
Western blotting, due to the presence of S1004 in inﬁltrating lympho-
cytes, as found in the present study. When the S100A4 levels in
epithelial cells were compared immunocytochemically (Table 2),
the proportion of specimens exhibiting epithelial staining for
S100A4 was more strongly signiﬁcantly different between carcinomas
and normal colon (P=0.0016, Fisher exact test) than when specimens
were compared using the quantitative RT–PCR technique (P=0.05,
Fisher exact test). The quantitative RT–PCR technique, like the
Western blotting used by Komatsu et al (2001) does not distinguish
between staining of epithelial and inﬁltrating host cells.
The present observation that all specimens contain immuno-
cytochemical staining of lymphocytic cells for S100A4 is consistent
with previous reports that S100A4 is found in human cells cultured
from the immune system, the promyelocytic leukaemia cell line,
HL-60 (Takenaga et al, 1994), the acute lymphoblastic leukaemia
cell line, MOLT-4, and human peripheral lymphocytes treated with
interleukin 2 (Tulchinsky et al, 1995), as well as in lymphocytes
associated with human breast cancer (Nikitenko et al, 2000;
Rudland et al, 2000). S100A4 is found in the immune cells of
the appendix, where it localizes to the T, and not the B lympho-
cytes. Whilst this specimen of appendix was of normal
appearance, it had been removed from a colon cancer patient,
but had been located at least 45 cm from the carcinoma in the
gut. Thus, the possibility cannot be entirely eliminated that the
appearance of S100A4 in the T cells of the appendix might have
been, in some way affected by the presence of the carcinoma cells
in the gut. The present experiments show, for the ﬁrst time, using
markers for T and B lymphocytes, that S100A4 is found exclusively
in T lymphocytes, not only in the immune cells of the appendix,
but also in specimens of colon carcinoma. The results suggest that
S100A4 may also have a normal role in cytotoxic immune reactions
as well as in metastasis of carcinoma cells.
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